H. Robert Superko/a4m.com
Aug 11, 2025, 06:08
New Data From WHS and ASPREE: Aspirin Heart Disease Prevention Conundrum
Maxima Mendez, Cardiologist, CEO of Cli-Lipid and the Cardiovascular Lipid Club, shared a post on X:
“New data from WHS and ASPREE:
Aspirin and Lpa
•LPA+ genotype → higher CVD risk, aspirin reduced events significantly (NNT: 38–34)
•LPA– genotype → normal CVD risk, bleeding risk outweighs benefit (NNT: 833–250)”
Read the full article here.
Article: The aspirin heart disease prevention conundrum
Authors: H. Robert Superko, John Sninsky, Brenda Garrett․
Stay updated with Hemostasis Today.
-
Aug 27, 2026, 11:08Sunisha Arora: New EBMT Recommendations Transform the Approach to HSCT in Thalassemia
-
Aug 27, 2026, 10:51Seema Dawood: A Layered Approach to Identifying Thalassemia in the Laboratory
-
Aug 27, 2026, 10:44Ed Smith: Vitalant Expands Hemophilia Center Team With New Career Opportunities
-
Aug 27, 2026, 10:43FDA Expands Hympavzi Approval to Children and Patients With Hemophilia A or B With Inhibitor
-
Aug 27, 2026, 10:28Narat Srivali: Exploring the Link Between Perioperative Corticosteroids and VTE Risk
-
Aug 27, 2026, 10:19Vincent Poher: Clinical Validation of Rapid Whole-Blood Fibrinogen Measurement
-
Aug 27, 2026, 07:49Denis Oduor: Bringing Blood Closer – Strengthening Kenya’s Response to PPH
-
Aug 27, 2026, 07:19Luis Oliverio Ambriz Garcia: ASH 2026 Guidelines – What’s New in ITP?
-
Aug 27, 2026, 06:58Priyam Bordoloi: The Biological Advantage of Two X Chromosomes